Case Report: AQP4-IgG-positive neuromyelitis optica spectrum disorder with CSF anti- NMDAR1 IgG positivity and encephalitic features - Report - MDSpire

Case Report: AQP4-IgG-positive neuromyelitis optica spectrum disorder with CSF anti- NMDAR1 IgG positivity and encephalitic features

  • By

  • Mingming Li

  • Lixia Chen

  • Yanjun Liu

  • Tiejun Gan

  • Jia Guo

  • July 13, 2026

Share

Clinical Case: Neuromyelitis Optica Spectrum Disorder Positive for AQP4-IgG

Background

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition characterized by the presence of AQP4-IgG antibodies, leading to severe neurological symptoms. The overlap between NMOSD and anti-NMDAR encephalitis is rare and can complicate diagnosis and treatment, particularly when initial symptoms are nonspecific. Understanding these overlaps is essential for accurate diagnosis.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • A 47-year-old woman presented with symptoms including anorexia, dizziness, and vomiting.
  • Brain MRI revealed a lesion in the anterior wall of the third ventricle, initially misdiagnosed as Wernicke encephalopathy.
  • CSF analysis showed positive AQP4-IgG and low-titer anti-NMDAR1 IgG.
  • The patient exhibited cognitive decline and neuropsychiatric symptoms, with MRI showing bilateral thalamic and mesial temporal abnormalities.
  • High-dose intravenous methylprednisolone followed by inebilizumab treatment led to substantial improvement in cognitive and visual functions.

Clinical Implications

Clinicians should consider NMOSD in patients presenting with encephalitic symptoms and atypical MRI findings. Vigilance for potential overlaps between NMOSD and anti-NMDAR encephalitis is necessary for accurate diagnosis.

Conclusion

This case illustrates the complexity of diagnosing autoimmune overlap syndromes and the importance of correlating clinical, imaging, and laboratory findings.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Comparison of clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without anti-connective tissue antibodies: an 18-month cohort follow-up
  2. Frontiers in Oncology, 2026 -- Case Report: Neuromyelitis optica spectrum disorder associated with gastric cardia and pancreatic cancers: clinical features and oncological implications
  3. Frontiers in Medicine, 2026 -- Ravulizumab for Relapse Prevention in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorder: A 2-Year Follow-Up Case Report
  4. Frontiers in Neurology, 2026 -- Anti-NMDA-receptor encephalitis and MOGAD associated optic neuritis: a case series
  5. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders | Neurology, 2019
  6. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults | Canadian Journal of Neurological Sciences, 2024
  7. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders | Neurology
  8. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults | Canadian Journal of Neurological Sciences | Cambridge Core

Original Source(s)

Related Content